For instance, to treat some forms of leukaemia, targeting and inhibiting JAKs could eliminate the effects of EPO signalling and perhaps prevent the development of leukaemia.[1] One example of a JAK inhibitor drug is Ruxolitinib, which is used as a JAK2 inhibitor.[2] STAT inhibitors are also being developed, and many of the inhibitors target STAT3.[3] It has been reported that therapies which target STAT3 can improve the survival of patients with cancer.[61] Another drug, called Tofacitinib, has been used for psoriasis and rheumatoid arthritis treatment.[4]